Methotrexate (MTX), an effective therapy for patients with psoriasis, was not able to cause significant reduction in the blood levels of IL-23, IL-17, IL-22, and Th17 cells in patients with rheumatoid arthritis [8, 9]. The gene discussed is IL22; the disease is psoriasis.